Ticker Details
Ovid Therapeutics Inc. Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
IPO Date:	May 10, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$434.96M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.42%
Avg Daily Range (30 D):	$0.10 | 4.59%
Avg Daily Range (90 D):	$0.08 | 4.15%

Institutional Daily Volume
Avg Daily Volume:	.59M
Avg Daily Volume (30 D):	3.71M
Avg Daily Volume (90 D):	2.21M

Trade Size
Avg Trade Size (Sh.):	214
Avg Trade Size (Sh.) (30 D):	217
Avg Trade Size (Sh.) (90 D):	248

Institutional Trades
Total Institutional Trades:	129
Avg Institutional Trade:	$2.05M
Avg Institutional Trade (30 D):	$1.56M
Avg Institutional Trade (90 D):	$1.51M
Avg Institutional Trade Volume:	.57M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.28M
Avg Closing Trade (30 D):	$2.02M
Avg Closing Trade (90 D):	$2.02M
Avg Closing Volume:	819.78K

News

Mar 18, 2026 @ 6:17 PM Here's Why Ovid Therapeutics Stock Popped Higher T... Source: Lee Samaha

Mar 18, 2026 @ 10:00 AM Ovid Therapeutics Announces Pricing of $60 Million... Source: Na

Nov 12, 2025 @ 12:00 PM Ovid Therapeutics Announces Planned Leadership Suc... Source: Ovid Therapeutics

Feb 27, 2025 @ 1:00 PM Ovid Therapeutics to Present at the TD Cowen 45th ... Source: N/A

Feb 20, 2025 @ 6:00 PM Epilepsy Market Assessment in the 7MM by 2034 ââ‚... Source: Delveinsight

Financials
	TTM	Q4 2025	FY 2025
Basic EPS
Diluted EPS
Revenue	$7.25M	$.72M	$7.25M
Gross Profit
Net Income / Loss	$-17.41M	$9.66M	$-17.41M
Operating Income / Loss	$-42.44M	$-12.29M	$-42.44M
Cost of Revenue
Net Cash Flow	$-12.98M	$-7.29M	$-12.98M
PE Ratio